Ligand Pharmaceuticals Inc (LGND) 89.75 $LGND
Shares of LGND Up 16.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Apr 24, 10:09AM CDT
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on March 31st, 2015 at $76.78. In approximately 3 weeks, Ligand Pharmaceuticals has returned 16.16% as of today's recent price of $89.19.
LGND: 89.75 (+0.83)
Ligand to Participate in Two Upcoming Investor Conferences
Business Wire - Fri Apr 24, 7:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences:
LGND: 89.75 (+0.83), DB: 34.26 (+0.11)
Ligand to Report First Quarter Results on May 11th
Business Wire - Thu Apr 23, 3:06PM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report first quarter 2015 financial results on May 11, 2015. Ligand's CEO John Higgins, President and COO Matt Foehr and Vice President of Finance & Strategy and CFO Nishan De Silva will host the conference call.
LGND: 89.75 (+0.83)
Ligand Names Melanie J. Herman Interim Chief Financial Officer
Business Wire - Thu Apr 23, 3:01PM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the appointment of Melanie J. Herman as interim Chief Financial Officer, effective May 21st. Ms. Herman currently serves as Ligand's Director of Accounting and Chief Accounting Officer. She succeeds Nishan de Silva, who has accepted the position of President and Chief Operating Officer at a privately held therapeutics-focused gene editing company and who has notified Ligand of his resignation, to be effective next month.
LGND: 89.75 (+0.83)
Ligand Earns Milestone from SAGE Therapeutics for SAGE-547
Business Wire - Wed Apr 22, 11:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has earned a $500,000 milestone payment from SAGE Therapeutics (SAGE) relating to the treatment of the first patient in SAGE's Phase 3 open-label expanded access protocol, designated Study 302. Study 302 is designed to offer SAGE-547 to patients affected by super-refractory status epilepticus (SRSE) and to evaluate the safety of SAGE-547 in patients with SRSE. SAGE has reported that the results from this clinical trial, along with results from SAGE's planned Phase 3 placebo-controlled clinical trial - called the STATUS Trial - and other clinical data obtained from the SAGE-547 development program are intended to form the basis of a New Drug Application (NDA) submission.
SAGE: 58.57 (-1.37), LGND: 89.75 (+0.83)
Looking For Action? S&P 1500 Most Volatile Stocks
Bespoke Investment Group - at Seeking Alpha - Tue Apr 21, 3:30AM CDT
For traders with a short-term time horizon who are looking for big moves over a short period, we have updated our list of the 50 S&P 1500 stocks trading above $10 that have the largest intraday high-low ranges (based on the average percent spread...
CRR: 31.60 (-1.26), NBR: 15.04 (-0.53), BCEI: 24.79 (-0.22), LL: 33.07 (-0.58), PTEN: 21.16 (-0.60), MNTA: 20.13 (+0.04), HOS: 20.56 (-0.22), KOP: 22.47 (+0.03), DO: 29.82 (-0.58), BBG: 10.01 (-0.12), SGY: 16.48 (-0.23), FTK: 14.06 (-0.43), SPN: 23.61 (-0.63), ROVI: 19.48 (+0.18), WPX: 13.19 (-0.14), AKRX: 55.24 (-0.68), MCF: 21.86 (+0.27), ZEUS: 11.52 (+0.04), LGND: 89.75 (+0.83), DEPO: 27.65 (+0.36), CCRN: 11.60 (+0.07), ESV: 24.04 (-0.23), ANIP: 70.26 (-1.52), SGNT: 25.20 (-0.40), PDCE: 55.50 (-0.47), NE: 15.67 (-0.40), UIHC: 21.02 (+0.03), TNGO: 14.32 (-0.10), SGMS: 12.80 (+0.20), GIFI: 14.36 (-0.98), TDW: 24.40 (-1.03), CENX: 13.04 (+0.10), UNT: 30.09 (-0.60), RIG: 16.40 (-0.57), SPOK: 20.91 (-0.03), GPRE: 31.77 (+0.44), SYRG: 12.39 (+0.01), GEOS: 21.09 (-0.48), CBM: 42.97 (+0.37), SM: 54.36 (-0.95), TESO: 12.59 (-0.24), ROSE: 22.13 (-0.16), RGEN: 34.75 (-0.25), VDSI: 25.64 (-0.39), SKYW: 14.04 (+0.23), GLF: 13.58 (-0.05), SLCA: 34.70 (-1.30), RDC: 19.26 (-0.28), EHTH: 13.50 (+2.06)
Ligand Partner TG Therapeutics Presents Positive Pre-clinical Data on IRAK4 Compounds at the American Association for Cancer Research (AACR) Annual Meeting
Business Wire - Mon Apr 20, 6:40AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner TG Therapeutics, Inc. (NASDAQ:TGTX) today announced the first presentation of preclinical data demonstrating single agent and combination activity of two of TG Therapeutics' IRAK4 inhibitor compounds under development. This pre-clinical data was presented yesterday at the 106th Annual Meeting of the American Association for Cancer Research (AACR), held in Philadelphia, PA.
TGTX: 16.23 (-0.18), LGND: 89.75 (+0.83)
Uptrend Call Working As Ligand Pharmaceuticals Stock Rises 12.5% (LGND)
Comtex SmarTrend(R) - Fri Apr 17, 9:44AM CDT
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on March 31st, 2015 at $76.78. In approximately 2 weeks, Ligand Pharmaceuticals has returned 12.52% as of today's recent price of $86.39.
LGND: 89.75 (+0.83)
Watch for Ligand Pharmaceuticals to Potentially Pullback After Gaining 2.27% Yesterday
Comtex SmarTrend(R) - Thu Apr 16, 5:20PM CDT
Ligand Pharmaceuticals (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $84.18 to a high of $87.17. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $85.11 on volume of 698,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LGND: 89.75 (+0.83)
Ligand Pharmaceuticals
at Investor's Business Daily - Fri Apr 10, 5:56PM CDT
Ligand Pharmaceuticals (LGND) will get higher royalty rates from Viking Therapeutics for 3 compounds under a revised agreement. Ligand stock rose 3.3% to 83.20.
LGND: 89.75 (+0.83)
Biotech Ligand Gets Sweeter Deal From Partner Viking
at Investor's Business Daily - Fri Apr 10, 3:36PM CDT
Shares of early-stage development biotech Ligand Pharmaceuticals (LGND) rose 3.3% to 83.20 after it disclosed that it would receive higher royalty rates on drugs licensed to partner Viking Therapeutics, which on Friday re-filed terms for an IPO. The...
PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), LGND: 89.75 (+0.83)
Ligand Pharma amends agreement with Viking Therapeutics before IPO
Seeking Alpha - at Seeking Alpha - Fri Apr 10, 9:23AM CDT
LGND: 89.75 (+0.83), VKTX: ()
The Best Small Cap Stocks To Buy Now
Todd Campbell - at Seeking Alpha - Mon Apr 06, 4:40AM CDT
PMC: 30.50 (-0.29), MATW: 50.80 (-0.20), ELLI: 57.75 (+0.69), SILC: 44.20 (+1.71), SGMO: 14.70 (-0.84), AFFX: 12.44 (-0.16), BABY: 42.15 (-0.01), HBIO: 6.22 (+0.08), EXAM: 43.13 (-0.04), IART: 61.31 (+0.84), SNCR: 51.48 (-0.44), CNMD: 53.40 (-0.83), BJRI: 49.52 (-3.92), NLNK: 52.10 (-0.90), CTRN: 24.69 (+0.29), ANAC: 64.49 (-2.10), PRSC: 49.35 (+0.02), RRGB: 83.32 (+1.41), ALOG: 88.06 (-0.13), DIOD: 27.28 (-0.72), LGND: 89.75 (+0.83), DEPO: 27.65 (+0.36), ASTE: 43.09 (+0.01), DYAX: 27.44 (-0.85), FARO: 43.44 (-1.22), ECOL: 49.43 (+0.31), PFPT: 54.33 (-2.60), MTSI: 31.41 (-1.92), IRWD: 15.10 (-0.38), ABAX: 63.62 (+0.31), ANIP: 70.26 (-1.52), FORM: 9.16 (-0.13), QLGC: 15.26 (+0.07), ADUS: 28.86 (+0.41), SNHY: 41.42 (+0.11), EBIX: 29.77 (-0.21), SWHC: 15.01 (+0.10)
3 Top-Rated Biotechs Could Take Buy Points Soon
at Investor's Business Daily - Tue Mar 31, 5:15PM CDT
Three highly rated stocks in the No. 1 Biomed/Biotech industry group are getting close to buy points: Ligand Pharmaceuticals (LGND), Amgen (AMGN) and Alexion Pharmaceuticals (ALXN). Watch this video to find out what their buy points are -- you may...
ALXN: 180.08 (-4.50), AMGN: 167.91 (-1.26), LGND: 89.75 (+0.83)
Fr. Emmanuel Lemelson Discusses Apple's Economic Prospects, World Wrestling Entertainment's Financial Condition And Other Issues
Amvona - Seeking Alpha - Mon Mar 30, 2:18PM CDT
(To listen to the full interview, click here ) On March 24, 2015, Rev. Father Emmanuel Lemelson, Founder and President of The Lantern Foundation and Chief Investment Officer of Lemelson Capital Management, appeared on Benzinga's Pre-Market Prep...
HLF: 41.10 (-3.75), GEOS: 21.09 (-0.48), KLIC: 15.49 (-0.19), WWE: 14.48 (-0.18), LGND: 89.75 (+0.83), LL: 33.07 (-0.58), AAPL: 130.28 (+0.61)
3 Up and Coming Biotech Stocks to Watch
Keith Speights, The Motley Fool - Motley Fool - Sun Mar 29, 1:02PM CDT
Source: Ligand Pharmaceuticals How hot is biotech these days? The top two exchange trade funds focusing on biotech stocks both more than tripled the performance of the S&P 500 index over the past 12 months. That's pretty hot. You might be...
PTLA: 38.51 (-0.85), CLDX: 30.10 (+0.19), LGND: 89.75 (+0.83)
Ligand Pharmaceuticals: Biotech's Jack Of All Trades
at Investor's Business Daily - Wed Mar 25, 4:20PM CDT
Call it a jack of all trades in biotech. Rather than just target a small number of drug therapies, Ligand Pharmaceuticals (LGND) focuses on a broad range of assets that address a host of diseases: multiple myeloma, hepatitis, Alzheimer's, diabetes,...
SAGE: 58.57 (-1.37), PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), RTRX: 24.75 (+0.01), AMGN: 167.91 (-1.26), LGND: 89.75 (+0.83), SPPI: 6.10 (+0.07), GSK: 46.59 (+0.28), NVS: 104.28 (-1.22)
Insider Trading Alert - TINY, OLED And LGND Traded By Insiders
at The Street - Mon Mar 23, 10:15AM CDT
Stocks with insider trader activity include TINY, OLED and LGND
OLED: 47.60 (+0.26), TINY: 3.12 (unch), LGND: 89.75 (+0.83)
The Best Small Cap Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Sat Mar 21, 11:24PM CDT
DMND: 29.91 (-0.42), PMC: 30.50 (-0.29), MATW: 50.80 (-0.20), ELLI: 57.75 (+0.69), WWE: 14.48 (-0.18), SILC: 44.20 (+1.71), SGMO: 14.70 (-0.84), TRNX: 26.25 (+0.01), OFIX: 36.46 (+0.10), AFFX: 12.44 (-0.16), CHE: 123.62 (+0.08), BABY: 42.15 (-0.01), HBIO: 6.22 (+0.08), IART: 61.31 (+0.84), SONC: 30.83 (-0.21), SNCR: 51.48 (-0.44), CNMD: 53.40 (-0.83), BJRI: 49.52 (-3.92), NLNK: 52.10 (-0.90), ANAC: 64.49 (-2.10), XSD: 85.14 (-2.91), PRSC: 49.35 (+0.02), RRGB: 83.32 (+1.41), IPAR: 31.75 (-0.88), ALOG: 88.06 (-0.13), DIOD: 27.28 (-0.72), NSIT: 28.68 (+0.01), LGND: 89.75 (+0.83), DEPO: 27.65 (+0.36), ASTE: 43.09 (+0.01), DYAX: 27.44 (-0.85), ECOL: 49.43 (+0.31), PFPT: 54.33 (-2.60), MTSI: 31.41 (-1.92), IRWD: 15.10 (-0.38), ABAX: 63.62 (+0.31), FLDM: 42.47 (-0.73), SCSS: 34.50 (+0.86), ANIP: 70.26 (-1.52), FORM: 9.16 (-0.13), BEAT: 8.60 (-0.26), QLGC: 15.26 (+0.07), ADUS: 28.86 (+0.41), PENX: 18.98 (+0.14), EBIX: 29.77 (-0.21), CORT: 6.32 (-0.12), SWHC: 15.01 (+0.10), OCFC: 17.32 (+0.42)
Uptrend Call Working As Ligand Pharmaceuticals Stock Rises 33.9% (LGND)
Comtex SmarTrend(R) - Fri Mar 20, 11:24AM CDT
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on February 19th, 2015 at $57.90. In approximately 4 weeks, Ligand Pharmaceuticals has returned 33.92% as of today's recent price of $77.54.
LGND: 89.75 (+0.83)
Shares of LGND Up 16.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Apr 24, 10:09AM CDT
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on March 31st, 2015 at $76.78. In approximately 3 weeks, Ligand Pharmaceuticals has returned 16.16% as of today's recent price of $89.19.
LGND: 89.75 (+0.83)
Ligand to Participate in Two Upcoming Investor Conferences
Business Wire - Fri Apr 24, 7:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences:
LGND: 89.75 (+0.83), DB: 34.26 (+0.11)
Ligand to Report First Quarter Results on May 11th
Business Wire - Thu Apr 23, 3:06PM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report first quarter 2015 financial results on May 11, 2015. Ligand's CEO John Higgins, President and COO Matt Foehr and Vice President of Finance & Strategy and CFO Nishan De Silva will host the conference call.
LGND: 89.75 (+0.83)
Ligand Names Melanie J. Herman Interim Chief Financial Officer
Business Wire - Thu Apr 23, 3:01PM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the appointment of Melanie J. Herman as interim Chief Financial Officer, effective May 21st. Ms. Herman currently serves as Ligand's Director of Accounting and Chief Accounting Officer. She succeeds Nishan de Silva, who has accepted the position of President and Chief Operating Officer at a privately held therapeutics-focused gene editing company and who has notified Ligand of his resignation, to be effective next month.
LGND: 89.75 (+0.83)
Ligand Earns Milestone from SAGE Therapeutics for SAGE-547
Business Wire - Wed Apr 22, 11:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has earned a $500,000 milestone payment from SAGE Therapeutics (SAGE) relating to the treatment of the first patient in SAGE's Phase 3 open-label expanded access protocol, designated Study 302. Study 302 is designed to offer SAGE-547 to patients affected by super-refractory status epilepticus (SRSE) and to evaluate the safety of SAGE-547 in patients with SRSE. SAGE has reported that the results from this clinical trial, along with results from SAGE's planned Phase 3 placebo-controlled clinical trial - called the STATUS Trial - and other clinical data obtained from the SAGE-547 development program are intended to form the basis of a New Drug Application (NDA) submission.
SAGE: 58.57 (-1.37), LGND: 89.75 (+0.83)
Looking For Action? S&P 1500 Most Volatile Stocks
Bespoke Investment Group - at Seeking Alpha - Tue Apr 21, 3:30AM CDT
For traders with a short-term time horizon who are looking for big moves over a short period, we have updated our list of the 50 S&P 1500 stocks trading above $10 that have the largest intraday high-low ranges (based on the average percent spread...
CRR: 31.60 (-1.26), NBR: 15.04 (-0.53), BCEI: 24.79 (-0.22), LL: 33.07 (-0.58), PTEN: 21.16 (-0.60), MNTA: 20.13 (+0.04), HOS: 20.56 (-0.22), KOP: 22.47 (+0.03), DO: 29.82 (-0.58), BBG: 10.01 (-0.12), SGY: 16.48 (-0.23), FTK: 14.06 (-0.43), SPN: 23.61 (-0.63), ROVI: 19.48 (+0.18), WPX: 13.19 (-0.14), AKRX: 55.24 (-0.68), MCF: 21.86 (+0.27), ZEUS: 11.52 (+0.04), LGND: 89.75 (+0.83), DEPO: 27.65 (+0.36), CCRN: 11.60 (+0.07), ESV: 24.04 (-0.23), ANIP: 70.26 (-1.52), SGNT: 25.20 (-0.40), PDCE: 55.50 (-0.47), NE: 15.67 (-0.40), UIHC: 21.02 (+0.03), TNGO: 14.32 (-0.10), SGMS: 12.80 (+0.20), GIFI: 14.36 (-0.98), TDW: 24.40 (-1.03), CENX: 13.04 (+0.10), UNT: 30.09 (-0.60), RIG: 16.40 (-0.57), SPOK: 20.91 (-0.03), GPRE: 31.77 (+0.44), SYRG: 12.39 (+0.01), GEOS: 21.09 (-0.48), CBM: 42.97 (+0.37), SM: 54.36 (-0.95), TESO: 12.59 (-0.24), ROSE: 22.13 (-0.16), RGEN: 34.75 (-0.25), VDSI: 25.64 (-0.39), SKYW: 14.04 (+0.23), GLF: 13.58 (-0.05), SLCA: 34.70 (-1.30), RDC: 19.26 (-0.28), EHTH: 13.50 (+2.06)
Ligand Partner TG Therapeutics Presents Positive Pre-clinical Data on IRAK4 Compounds at the American Association for Cancer Research (AACR) Annual Meeting
Business Wire - Mon Apr 20, 6:40AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner TG Therapeutics, Inc. (NASDAQ:TGTX) today announced the first presentation of preclinical data demonstrating single agent and combination activity of two of TG Therapeutics' IRAK4 inhibitor compounds under development. This pre-clinical data was presented yesterday at the 106th Annual Meeting of the American Association for Cancer Research (AACR), held in Philadelphia, PA.
TGTX: 16.23 (-0.18), LGND: 89.75 (+0.83)
Uptrend Call Working As Ligand Pharmaceuticals Stock Rises 12.5% (LGND)
Comtex SmarTrend(R) - Fri Apr 17, 9:44AM CDT
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on March 31st, 2015 at $76.78. In approximately 2 weeks, Ligand Pharmaceuticals has returned 12.52% as of today's recent price of $86.39.
LGND: 89.75 (+0.83)
Watch for Ligand Pharmaceuticals to Potentially Pullback After Gaining 2.27% Yesterday
Comtex SmarTrend(R) - Thu Apr 16, 5:20PM CDT
Ligand Pharmaceuticals (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $84.18 to a high of $87.17. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $85.11 on volume of 698,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LGND: 89.75 (+0.83)
Ligand Pharmaceuticals
at Investor's Business Daily - Fri Apr 10, 5:56PM CDT
Ligand Pharmaceuticals (LGND) will get higher royalty rates from Viking Therapeutics for 3 compounds under a revised agreement. Ligand stock rose 3.3% to 83.20.
LGND: 89.75 (+0.83)
Biotech Ligand Gets Sweeter Deal From Partner Viking
at Investor's Business Daily - Fri Apr 10, 3:36PM CDT
Shares of early-stage development biotech Ligand Pharmaceuticals (LGND) rose 3.3% to 83.20 after it disclosed that it would receive higher royalty rates on drugs licensed to partner Viking Therapeutics, which on Friday re-filed terms for an IPO. The...
PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), LGND: 89.75 (+0.83)
Ligand Pharma amends agreement with Viking Therapeutics before IPO
Seeking Alpha - at Seeking Alpha - Fri Apr 10, 9:23AM CDT
LGND: 89.75 (+0.83), VKTX: ()
The Best Small Cap Stocks To Buy Now
Todd Campbell - at Seeking Alpha - Mon Apr 06, 4:40AM CDT
PMC: 30.50 (-0.29), MATW: 50.80 (-0.20), ELLI: 57.75 (+0.69), SILC: 44.20 (+1.71), SGMO: 14.70 (-0.84), AFFX: 12.44 (-0.16), BABY: 42.15 (-0.01), HBIO: 6.22 (+0.08), EXAM: 43.13 (-0.04), IART: 61.31 (+0.84), SNCR: 51.48 (-0.44), CNMD: 53.40 (-0.83), BJRI: 49.52 (-3.92), NLNK: 52.10 (-0.90), CTRN: 24.69 (+0.29), ANAC: 64.49 (-2.10), PRSC: 49.35 (+0.02), RRGB: 83.32 (+1.41), ALOG: 88.06 (-0.13), DIOD: 27.28 (-0.72), LGND: 89.75 (+0.83), DEPO: 27.65 (+0.36), ASTE: 43.09 (+0.01), DYAX: 27.44 (-0.85), FARO: 43.44 (-1.22), ECOL: 49.43 (+0.31), PFPT: 54.33 (-2.60), MTSI: 31.41 (-1.92), IRWD: 15.10 (-0.38), ABAX: 63.62 (+0.31), ANIP: 70.26 (-1.52), FORM: 9.16 (-0.13), QLGC: 15.26 (+0.07), ADUS: 28.86 (+0.41), SNHY: 41.42 (+0.11), EBIX: 29.77 (-0.21), SWHC: 15.01 (+0.10)
3 Top-Rated Biotechs Could Take Buy Points Soon
at Investor's Business Daily - Tue Mar 31, 5:15PM CDT
Three highly rated stocks in the No. 1 Biomed/Biotech industry group are getting close to buy points: Ligand Pharmaceuticals (LGND), Amgen (AMGN) and Alexion Pharmaceuticals (ALXN). Watch this video to find out what their buy points are -- you may...
ALXN: 180.08 (-4.50), AMGN: 167.91 (-1.26), LGND: 89.75 (+0.83)
Fr. Emmanuel Lemelson Discusses Apple's Economic Prospects, World Wrestling Entertainment's Financial Condition And Other Issues
Amvona - Seeking Alpha - Mon Mar 30, 2:18PM CDT
(To listen to the full interview, click here ) On March 24, 2015, Rev. Father Emmanuel Lemelson, Founder and President of The Lantern Foundation and Chief Investment Officer of Lemelson Capital Management, appeared on Benzinga's Pre-Market Prep...
HLF: 41.10 (-3.75), GEOS: 21.09 (-0.48), KLIC: 15.49 (-0.19), WWE: 14.48 (-0.18), LGND: 89.75 (+0.83), LL: 33.07 (-0.58), AAPL: 130.28 (+0.61)
3 Up and Coming Biotech Stocks to Watch
Keith Speights, The Motley Fool - Motley Fool - Sun Mar 29, 1:02PM CDT
Source: Ligand Pharmaceuticals How hot is biotech these days? The top two exchange trade funds focusing on biotech stocks both more than tripled the performance of the S&P 500 index over the past 12 months. That's pretty hot. You might be...
PTLA: 38.51 (-0.85), CLDX: 30.10 (+0.19), LGND: 89.75 (+0.83)
Ligand Pharmaceuticals: Biotech's Jack Of All Trades
at Investor's Business Daily - Wed Mar 25, 4:20PM CDT
Call it a jack of all trades in biotech. Rather than just target a small number of drug therapies, Ligand Pharmaceuticals (LGND) focuses on a broad range of assets that address a host of diseases: multiple myeloma, hepatitis, Alzheimer's, diabetes,...
SAGE: 58.57 (-1.37), PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), RTRX: 24.75 (+0.01), AMGN: 167.91 (-1.26), LGND: 89.75 (+0.83), SPPI: 6.10 (+0.07), GSK: 46.59 (+0.28), NVS: 104.28 (-1.22)
Insider Trading Alert - TINY, OLED And LGND Traded By Insiders
at The Street - Mon Mar 23, 10:15AM CDT
Stocks with insider trader activity include TINY, OLED and LGND
OLED: 47.60 (+0.26), TINY: 3.12 (unch), LGND: 89.75 (+0.83)
The Best Small Cap Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Sat Mar 21, 11:24PM CDT
DMND: 29.91 (-0.42), PMC: 30.50 (-0.29), MATW: 50.80 (-0.20), ELLI: 57.75 (+0.69), WWE: 14.48 (-0.18), SILC: 44.20 (+1.71), SGMO: 14.70 (-0.84), TRNX: 26.25 (+0.01), OFIX: 36.46 (+0.10), AFFX: 12.44 (-0.16), CHE: 123.62 (+0.08), BABY: 42.15 (-0.01), HBIO: 6.22 (+0.08), IART: 61.31 (+0.84), SONC: 30.83 (-0.21), SNCR: 51.48 (-0.44), CNMD: 53.40 (-0.83), BJRI: 49.52 (-3.92), NLNK: 52.10 (-0.90), ANAC: 64.49 (-2.10), XSD: 85.14 (-2.91), PRSC: 49.35 (+0.02), RRGB: 83.32 (+1.41), IPAR: 31.75 (-0.88), ALOG: 88.06 (-0.13), DIOD: 27.28 (-0.72), NSIT: 28.68 (+0.01), LGND: 89.75 (+0.83), DEPO: 27.65 (+0.36), ASTE: 43.09 (+0.01), DYAX: 27.44 (-0.85), ECOL: 49.43 (+0.31), PFPT: 54.33 (-2.60), MTSI: 31.41 (-1.92), IRWD: 15.10 (-0.38), ABAX: 63.62 (+0.31), FLDM: 42.47 (-0.73), SCSS: 34.50 (+0.86), ANIP: 70.26 (-1.52), FORM: 9.16 (-0.13), BEAT: 8.60 (-0.26), QLGC: 15.26 (+0.07), ADUS: 28.86 (+0.41), PENX: 18.98 (+0.14), EBIX: 29.77 (-0.21), CORT: 6.32 (-0.12), SWHC: 15.01 (+0.10), OCFC: 17.32 (+0.42)
Uptrend Call Working As Ligand Pharmaceuticals Stock Rises 33.9% (LGND)
Comtex SmarTrend(R) - Fri Mar 20, 11:24AM CDT
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on February 19th, 2015 at $57.90. In approximately 4 weeks, Ligand Pharmaceuticals has returned 33.92% as of today's recent price of $77.54.
LGND: 89.75 (+0.83)
